Ketokonazol HRA 200 mg tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ketokonazol hra 200 mg tablete

laboratoire hra pharma - ketokonazol - tableta - ketokonazol 200 mg / 1 tableta - ketokonazol

Lomexin 600 mg mehke vaginalne kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lomexin 600 mg mehke vaginalne kapsule

recordati ireland ltd. - fentikonazolijev nitrat - vaginalna kapsula, mehka - fentikonazolijev nitrat 600 mg / 1 kapsula - fentikonazol

Lomexin 200 mg mehke vaginalne kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lomexin 200 mg mehke vaginalne kapsule

recordati ireland ltd. - fentikonazolijev nitrat - vaginalna kapsula, mehka - fentikonazolijev nitrat 200 mg / 1 kapsula - fentikonazol

Lomexin 20 mg/g vaginalna krema Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lomexin 20 mg/g vaginalna krema

recordati ireland ltd. - fentikonazolijev nitrat - vaginalna krema - fentikonazolijev nitrat 20 mg / 1 g - fentikonazol

Oronazol 20 mg/g krema Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oronazol 20 mg/g krema

krka, d.d., novo mesto - ketokonazol - krema - ketokonazol 20 mg / 1 g - ketokonazol

Oronazol 20 mg/g zdravilni šampon Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oronazol 20 mg/g zdravilni šampon

johnson & johnson d.o.o. - ketokonazol - zdravilni šampon - ketokonazol 20 mg / 1 g - ketokonazol

Ketoconazole HRA Evropska unija - slovenščina - EMA (European Medicines Agency)

ketoconazole hra

hra pharma rare diseases - ketokonazol - cushingov sindrom - antimikotiki za sistemsko uporabo - ketokonazol hra je indiciran za zdravljenje endogenega cushingovega sindroma pri odraslih in mladostnikih, starejših od 12 let.

Imatinib Koanaa Evropska unija - slovenščina - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. bolniki, ki imajo nizko ali zelo nizko tveganje za ponovitev, ne bi smel imeti adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.

FUNGICONAZOL Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fungiconazol

dechra regulatory -

Cresemba Evropska unija - slovenščina - EMA (European Medicines Agency)

cresemba

basilea pharmaceutica deutschland gmbh - isavukonazol - aspergiloza - cresemba je navedeno pri odraslih za zdravljenje:invazivne aspergillosismucormycosis pri bolnikih, za katere amphotericin b je inappropriateconsideration treba uradna smernice za ustrezno uporabo protiglivično agenti.